Stock Earnings

Question 1

Nykode Therapeutics ASAの主要な財務諸表は何ですか？

Accepted Answer

最新の財務諸表（Form-10K）によると、Nykode Therapeutics ASAの総資産は$153で、純lossは$-38です。

Question 2

VACBFの主要な財務比率は何ですか？

Accepted Answer

Nykode Therapeutics ASAの流動比率は9、純利益率は-475、1株当たり売上高は$0.02です。

Question 3

Nykode Therapeutics ASAの収益はセグメントまたは地域別にどのように分けられていますか？

Accepted Answer

Nykode Therapeutics ASA largest revenue segment is Novel Vaccines and Immunotherapies, at a revenue of 136,380,103 in the most earnings release.For geography, United States is the primary market for Nykode Therapeutics ASA, at a revenue of 136,380,103.

Question 4

Nykode Therapeutics ASAは収益を上げていますか？

Accepted Answer

no、最新の財務諸表によると、Nykode Therapeutics ASAの純lossは$-38です。

Question 5

Nykode Therapeutics ASAに負債はありますか？

Accepted Answer

yes、Nykode Therapeutics ASAの負債は17です。

Question 6

Nykode Therapeutics ASAの発行済株式数は何株ですか？

Accepted Answer

Nykode Therapeutics ASAの総発行済株式数は326.54株です。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	7	8	12	7	33	215
Revenue Growth (YoY)	-30%	-33%	71%	-79%	-85%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	25	31	28	18	17	16
Research & Development	--	--	29	26	16	10
Operating Expenses	48	55	69	57	41	33
Other Non Operating Income (Expenses)	--	0	0	0	0	0
Pretax Income	-32	-45	-44	-50	-11	180
Income Tax Expense	-7	-6	-8	-8	-1	31
Net Income	-25	-38	-35	-42	-9	149
Net Income Growth	-36%	9%	-17%	367%	-106%	-1,246%
Shares Outstanding (Diluted)	326.54	326.54	300.52	290.11	286.34	296.14
Shares Change (YoY)	9%	9%	4%	1%	-3%	438.99%
EPS (Diluted)	-0.07	-0.11	-0.11	-0.14	-0.03	0.5
EPS Growth	-42%	2%	-21%	348%	-107%	-303%
Free Cash Flow	-47	-51	-98	-23	0	180
Free Cash Flow Per Share	-0.14	-0.15	-0.32	-0.07	0	0.6
Gross Margin	--	--	--	--	--	--
Operating Margin	-571.42%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
Profit Margin	-357.14%	-475%	-291.66%	-600%	-27.27%	69.3%
Free Cash Flow Margin	-671.42%	-637.5%	-816.66%	-328.57%	0%	83.72%
EBITDA	-38	-45	-54	-49	-7	181
EBITDA Margin	-542.85%	-562.5%	-450%	-700%	-21.21%	84.18%
D&A For EBITDA	2	2	2	1	0	0
EBIT	-40	-47	-56	-50	-7	181
EBIT Margin	-571.42%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
Effective Tax Rate	21.87%	13.33%	18.18%	16%	9.09%	17.22%

Nykode Therapeutics ASA (VACBF) Price

VACBF Stock Price Chart

VACBF Income

Follow-Up Questions